Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
While Sutro shows why it’s shelved luvelta-T.
The company buys Belgium’s EsoBiotec for $425m.
The acquisition of Araris follows a 2023 discovery collaboration.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
The Japanese group licenses sapablursen from Ionis for $280m.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
